

This is a list of guidelines for the safety of veterinary medicines as issued by the European Medicines Agency (EMA) and the International Veterinary Conference on Harmonization (VICH).

The page is structured and contains instructions from the field of toxicology, user safety, environmental safety, and guidance on residue safety assessment (lead times, MRLs). Please click here: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000384.jsp&mid=WC0b01ac058002dd37

In addition to the guidelines mentioned below, the EMA also publishes and updates a list of frequently asked questions and answers concerning MRL determination, please click here: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000039.jsp&mid=WC0b01ac058002d89b

List of scientific guidelines on the safety - part III.A :

TOXICOLOGY

Name	Number	Effective from	Note
VICH GL22 Safety studies for veterinary drugs in human food: reproduction	ICM/Veterinary/525/2000	07/2002	Final studies
VICH GL23 Studies to evaluate the safety of veterinary drugs in human food: genotoxicity	ICM/Veterinary/526/2000	07/2002	Final
VICH GL28 Studies to evaluate the safety of veterinary drugs in human food: carcinogenicity testing	ICM/Veterinary/451/2001 Rev.01/06/2006	06/2006	Gen
VICH GL31 Safety studies for veterinary drugs in human food: repeat-dose (90) toxicity testing	ICM/Veterinary/484/2002	06/2004	Final
VICH GL32 Studies to evaluate the safety of veterinary drugs in human food: adopted by CVMP	ICM/Veterinary/485/2002	06/2004	Final
VICH GL33 Safety studies for veterinary drugs in human food: general approach to testing	EMA/ICM/Veterinary/486/02/06/2004	06/2004	Approach
VICH GL37 Safety of veterinary drugs in human food: repeated (chronic) toxicity testing	ICM/Veterinary/468/2003	30/05/2005	Final
VICH GL54 Studies to evaluate the safety of veterinary drugs in human food: general approach	EMA/ICM/Veterinary/639/25/2010/01/2017	01/2017	Final
Assessment and control of residues of veterinary medicines in human food	EMA/CVMP/Veterinary/672/15/2016	15/2016	Drafting guidelines
Regulatory acceptance of veterinary medicines in human food: testing approaches	EMA/ICM/Veterinary/673/15/2016	15/2016	Testing approaches

Part III Safety and Residues Tests

Written by Leona Nepejchalová - Last Updated Wednesday, 15 May 2019 10:22

USER SAFETY

Name	Number	Effective from	Note
User safety for pharmaceuticals	EMA/CVMP/ERA/5142/2010	10/2010	Rev. 1
User safety of topically administered products	EMA/CVMP/ERA/721059/2014		Draft guideline

ENVIRONMENTAL RISK ASSESSMENT

Name	Number	Effective from	Note
VICH GL6 Environmental impact assessment (EIS) for medicinal products	EMA/CVMP/ERA/5921/2009	07/2009	Guideline Phase I
VICH GL38 Environmental impact assessment for veterinary medicinal products	EMA/CVMP/ERA/1828/2005	10/2005	Guideline
Environmental impact assessment of support of medicinal products	EMA/CVMP/ERA/1828/2005	10/2005	Reflection paper (2016)
Assessment of persistent, bioaccumulative and toxic (PBT) substances	EMA/CVMP/ERA/52740/2012	04/2016	Guideline
Assessment of persistent, bioaccumulative and toxic (PBT) substances	EMA/CVMP/ERA/52740/2012	04/2016	Guideline
Authorisation of veterinary medicinal products containing (potential) persistent, bioaccumulative and toxic (PBT) substances	EMA/CVMP/ERA/40621/2015		Reflection paper
Determining the fate of veterinary medicinal products in the environment	EMA/CVMP/ERA/40023/2009	01/2011	Guideline
Higher-tier testing of veterinary medicinal products on fauna	EMA/CVMP/ERA/40935/2010		Draft guideline
Plant testing strategy for veterinary medicinal product	EMA/CVMP/ERA/689041/2015	10/2017	Guideline
Assessing the toxicological impact of veterinary medicinal products on freshwater communities	EMA/CVMP/ERA/110355/2015		Guideline
Poorly extractable and/or non-extractable residues	EMA/CVMP/ERA/34925/2014		Reflection paper
Risk-mitigation measures related to the assessment of veterinary medicinal products	EMA/CVMP/ERA/40935/2010		Reflection paper
ERA - QaA document	EMA/CVMP/ERA/172074/2008	Rev.6	Rev. 6
Antimicrobial resistance in the environment	EMA/CVMP/ERA/632109/2014		
Draft Reflection paper			

List of scientific guidelines on the safety - part III.B :

RESIDUES/WITHDRAWAL PERIODS

Part III Safety and Residues Tests

Written by Leona Nepejchalová - Last Updated Wednesday, 15 May 2019 10:22

Name	Number	Effective from	Note
Approach towards harmonisation of withdrawal periods	EMA/CVMP/036/1995/01/01/1997	01/01/1997	Under revision
Updated application software: withdrawal time calculation for tissues	EMA/CVMP/473/1998/08/09/2000	08/09/2000	web page EMA
Determination of withdrawal periods for milk	EMA/CVMP/542/2003	13/04/2005	Under revision
Updated application software: withdrawal time calculation for milk	EMA/CVMP/542/2003	13/04/2005	web page EMA
Injection-site residues	EMA/CVMP/542/2003	13/04/2005	-
Setting health based exposure limits for residues in the muscle	EMA/CVMP/542/2003	13/04/2005	Under revision
VICH GL46 studies to evaluate the kinetics of veterinary drugs in food-producing animals	EMA/CVMP/542/2003	13/04/2005	Under revision
VICH GL47 studies to evaluate the kinetics of veterinary drugs in food-producing animals	EMA/CVMP/542/2003	13/04/2005	Under revision
VICH GL48 studies to evaluate the kinetics of veterinary drugs in food-producing animals	EMA/CVMP/542/2003	13/04/2005	Under revision
VICH GL49 studies to evaluate the kinetics of veterinary drugs in food-producing animals	EMA/CVMP/542/2003	13/04/2005	Under revision
VICH GL56 studies to evaluate the kinetics of veterinary drugs in food-producing animals	EMA/CVMP/542/2003	13/04/2005	Under revision
VICH GL57 on studies to evaluate the kinetics of veterinary drugs in food-producing animals	EMA/CVMP/542/2003	13/04/2005	Under revision
Injection-site residues: Consideration of residues in the muscle and residue levels in the milk	EMA/CVMP/542/2003	13/04/2005	Reflection papers
Introducing a review and update of residues in the muscle and residue levels in the milk	EMA/CVMP/542/2003	13/04/2005	Concept papers

MAXIMUM RESIDUE LIMITS (MRL'S)

Name	Number	Effective from	Note
Approach to establish a pharmacokinetic model for the calculation of MRLs (ADI)	CVMP/SWP/355/2006/01/06/2006	06/06/2006	-
Data to be provided in support of applications for MRLs in the list of substances considered for MRLs	EMA/CVMP/516/2009/01/05/2011	05/05/2011	-
Risk-analysis approach for MRLs in food of animal origin	EMA/CVMP/87/00/04/2001	04/04/2001	-
VICH GL36 Studies to evaluate the residues of veterinary drugs in human food: General approach	EMA/CVMP/VICH/467/2000/01/05/2012	05/05/2012	-
Assessment of bioavailability of residues of animal origin in human food	EMA/CVMP/SWP/95/02/2009/2008	02/02/2008	Reflection papers
Consideration of adjuvants under Council Regulation (EEC) No 2377/90	CVMP/339/16/2007	17/12/2007	Reflection papers
New approach developed by the WHO for the calculation of MRLs	CVMP/SWP/138/2006/02/09/2008	09/02/2008	Reflection papers
Approaches on how to consider MRLs in the context of Council Regulation 2377/90	EMA/CVMP/123/05/2005/21/2005	21/11/2005	Reflection papers
Definition of substances capable of being considered for MRLs in the context of Council Regulation 2377/90	CVMP/022/1997	30/04/2000	Reflection papers
Establishment of maximum residue limits for residues in the muscle and residue levels in the milk	EMA/CVMP/391/2002	01/11/2002	Reflection Paper

AVAILABILITY (MINOR USES / MINOR SPECIES)

Name	Number	Effective from	Note
Guideline on safety and residues of veterinary medicinal products	EMA/CVMP/SWP/687/12/06/19/2016	19/06/2016	-
Note regarding CVMP guidelines for the calculation of MRLs for veterinary medicinal products intended for use in minor species	EMA/CVMP/1336/12/2005/07/2006	07/07/2006	-
Establishment of MRLs for residues in the muscle and residue levels in the milk for fin fish	EMA/CVMP/15/97	01/01/1998	-

Part III Safety and Residues Tests

Written by Leona Nepejchalová - Last Updated Wednesday, 15 May 2019 10:22

Position paper regarding availability of data for medicinal products - extrapolation of maximum residue limits

MULTIDISCIPLINARY

Name	Number	Effective from	Note
Guideline on pharmaceuticals	EMA/CMP/3304/05	18/12/2006	-
Investigation of chiral active substances	1/351/91	01/10/1993	-